Published in Biochemistry on November 05, 1985
Heparan sulfate proteoglycans. Cold Spring Harb Perspect Biol (2011) 2.96
Lessons learned from the contamination of heparin. Nat Prod Rep (2009) 2.81
Using an enzymatic combinatorial approach to identify anticoagulant heparan sulfate structures. Chem Biol (2007) 2.20
Enzymatic redesigning of biologically active heparan sulfate. J Biol Chem (2005) 1.89
Heparan sulfate proteoglycans of the cardiovascular system. Specific structures emerge but how is synthesis regulated? J Clin Invest (1997) 1.75
Chemoenzymatic design of heparan sulfate oligosaccharides. J Biol Chem (2010) 1.64
Glycosaminoglycans and the regulation of blood coagulation. Biochem J (1993) 1.57
Disruption of PF4/H multimolecular complex formation with a minimally anticoagulant heparin (ODSH). Thromb Haemost (2012) 1.45
Anticoagulant heparan sulfate: structural specificity and biosynthesis. Appl Microbiol Biotechnol (2006) 1.42
Enzymatic synthesis of heparin related polysaccharides on sensor chips: rapid screening of heparin-protein interactions. Biochem Biophys Res Commun (2005) 1.29
Homogeneous low-molecular-weight heparins with reversible anticoagulant activity. Nat Chem Biol (2014) 1.20
Dissecting the substrate recognition of 3-O-sulfotransferase for the biosynthesis of anticoagulant heparin. Proc Natl Acad Sci U S A (2012) 1.11
Characterization of heparin oligosaccharides binding specifically to antithrombin III using mass spectrometry. Biochemistry (2008) 1.04
Mice deficient in heparan sulfate 3-O-sulfotransferase-1: normal hemostasis with unexpected perinatal phenotypes. Glycoconj J (2003) 1.03
The human estrogen sulfotransferase: a half-site reactive enzyme. Biochemistry (2010) 1.02
Enzymatic synthesis of glycosaminoglycan heparin. Semin Thromb Hemost (2007) 1.00
Heparan sulfate 3-O-sulfation: a rare modification in search of a function. Matrix Biol (2013) 0.98
Chemoenzymatic synthesis of heparin oligosaccharides with both anti-factor Xa and anti-factor IIa activities. J Biol Chem (2012) 0.96
Portable sulphotransferase domain determines sequence specificity of heparan sulphate 3-O-sulphotransferases. Biochem J (2001) 0.96
Biosynthesis of heparin. Use of Escherichia coli K5 capsular polysaccharide as a model substrate in enzymic polymer-modification reactions. Biochem J (1991) 0.95
Inhibition of leucocyte elastase by heparin and its derivatives. Biochem J (1988) 0.92
Screening for anticoagulant heparan sulfate octasaccharides and fine structure characterization using tandem mass spectrometry. Biochemistry (2010) 0.92
Understanding the substrate specificity of the heparan sulfate sulfotransferases by an integrated biosynthetic and crystallographic approach. Curr Opin Struct Biol (2012) 0.91
The signature 3-O-sulfo group of the anticoagulant heparin sequence is critical for heparin binding to antithrombin but is not required for allosteric activation. J Biol Chem (2009) 0.90
Differentiation of 3-O-sulfated heparin disaccharide isomers: identification of structural aspects of the heparin CCL2 binding motif. J Am Soc Mass Spectrom (2008) 0.89
Probing structural selectivity of synthetic heparin binding to Stabilin protein receptors. J Biol Chem (2012) 0.89
Anti-thrombin activities of heparin. Effect of saccharide chain length on thrombin inhibition by heparin cofactor II and by antithrombin. Biochem J (1989) 0.87
Basement-membrane heparan sulphate with high affinity for antithrombin synthesized by normal and transformed mouse mammary epithelial cells. Biochem J (1987) 0.87
A computational framework for heparan sulfate sequencing using high-resolution tandem mass spectra. Mol Cell Proteomics (2014) 0.85
Isolation and characterization of a heparin with low antithrombin activity from the body of Styela plicata (Chordata-Tunicata). Distinct effects on venous and arterial models of thrombosis. Thromb Res (2007) 0.84
Degradation of heparin proteoglycan in cultured mouse mastocytoma cells. Biochem J (1987) 0.84
Directing the biological activities of heparan sulfate oligosaccharides using a chemoenzymatic approach. Glycobiology (2011) 0.84
Structural Analysis of Heparin-Derived 3-O-Sulfated Tetrasaccharides: Antithrombin Binding Site Variants. J Pharm Sci (2016) 0.83
Heparan sulfate and heparin interactions with proteins. J R Soc Interface (2015) 0.83
Characterizing the microstructure of heparin and heparan sulfate using N-sulfoglucosamine 1H and 15N NMR chemical shift analysis. Anal Chem (2012) 0.82
Stable heparin-producing cell lines derived from the Furth murine mastocytoma. Proc Natl Acad Sci U S A (1992) 0.82
Structural and functional properties of heparin analogues obtained by chemical sulphation of Escherichia coli K5 capsular polysaccharide. Biochem J (1995) 0.81
A Golgi-on-a-chip for glycan synthesis. Nat Chem Biol (2009) 0.80
A Simple Method for Discovering Druggable, Specific Glycosaminoglycan-Protein Systems. Elucidation of Key Principles from Heparin/Heparan Sulfate-Binding Proteins. PLoS One (2015) 0.80
Characterization of the conformational alterations, reduced anticoagulant activity, and enhanced antiangiogenic activity of prelatent antithrombin. J Biol Chem (2008) 0.80
Cell mutants defective in synthesizing a heparan sulfate proteoglycan with regions of defined monosaccharide sequence. Proc Natl Acad Sci U S A (1990) 0.80
Substrate specificity of 6-O-endosulfatase (Sulf-2) and its implications in synthesizing anticoagulant heparan sulfate. Glycobiology (2012) 0.79
Modification degrees at specific sites on heparan sulphate: an approach to measure chemical modifications on biological molecules with stable isotope labelling. Biochem J (2005) 0.78
Optimization of bioprocess conditions improves production of a CHO cell-derived, bioengineered heparin. Biotechnol J (2015) 0.77
Discovery of a heparan sulfate 3-O-sulfation specific peeling reaction. Anal Chem (2014) 0.77
Heparan sulphate, its derivatives and analogues share structural characteristics that can be exploited, particularly in inhibiting microbial attachment. Braz J Med Biol Res (2012) 0.76
Interactions between nattokinase and heparin/GAGs. Glycoconj J (2015) 0.75
Neutralizing the anticoagulant activity of ultra-low-molecular-weight heparins using N-acetylglucosamine 6-sulfatase. FEBS J (2013) 0.75
Uncovering the Relationship between Sulphation Patterns and Conformation of Iduronic Acid in Heparan Sulphate. Sci Rep (2016) 0.75
The design and synthesis of new synthetic low-molecular-weight heparins. J Thromb Haemost (2016) 0.75
Combinatorial enzymatic synthesis of heparan sulfate. Chem Biol (2007) 0.75
HS3ST1 genotype regulates antithrombin's inflammomodulatory tone and associates with atherosclerosis. Matrix Biol (2017) 0.75
Synthesis of 3-O-Sulfated Oligosaccharides to Understand the Relationship between Structures and Functions of Heparan Sulfate. J Am Chem Soc (2017) 0.75
The Good the Bad and the Ugly of Glycosaminoglycans in Tissue Engineering Applications. Pharmaceuticals (Basel) (2017) 0.75
Breast Cancer Surveillance Consortium: a national mammography screening and outcomes database. AJR Am J Roentgenol (1997) 7.62
A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. Cell (1999) 6.82
Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA (2005) 5.60
Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med (1999) 4.44
The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem (1973) 4.24
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
Enhancement of nonspecific immunity to Klebsiella pneumoniae infection by a synthetic immunoadjuvant (N-acetylmuramyl-L-alanyl-D-isoglutamine) and several analogs. Proc Natl Acad Sci U S A (1977) 3.31
The anticoagulant activation of antithrombin by heparin. Proc Natl Acad Sci U S A (1997) 3.09
The separation of active and inactive forms of heparin. Biochem Biophys Res Commun (1976) 2.91
Modulation of the immune response by a synthetic adjuvant and analogs. Proc Natl Acad Sci U S A (1976) 2.82
Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med (1990) 2.82
Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature (1992) 2.73
Distinctive adjuvanticity of synthetic analogs of mycobacterial water-soluble components. Cell Immunol (1976) 2.61
Benefits versus risks from mammography: a critical reassessment. Cancer (1996) 2.43
Synthesis of thrombin-inhibiting heparin mimetics without side effects. Nature (1999) 2.27
Anticoagulant action of heparin. Nature (1973) 2.26
Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem (1992) 2.24
Isolation of a src homology 2-containing tyrosine phosphatase. Proc Natl Acad Sci U S A (1992) 2.22
Mechanism of precipitation of proteins by polyethylene glycols. Analysis in terms of excluded volume. J Biol Chem (1981) 2.14
A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J Clin Invest (1998) 2.08
Actions and interactions of antithrombin and heparin. N Engl J Med (1975) 2.06
Current medicolegal and confidentiality issues in large, multicenter research programs. Am J Epidemiol (2000) 2.06
Cloned bovine aortic endothelial cells synthesize anticoagulantly active heparan sulfate proteoglycan. J Biol Chem (1986) 2.02
Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin. Circ Res (1980) 2.00
Inhibition of vascular smooth muscle cell growth by endothelial cell-derived heparin. Possible role of a platelet endoglycosidase. J Biol Chem (1982) 1.99
Isolation and characterization of endothelial progenitor cells from mouse embryos. Development (1998) 1.94
Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J Thromb Haemost (2004) 1.91
Mast cell clones: a model for the analysis of cellular maturation. J Cell Biol (1982) 1.91
PR39, a peptide regulator of angiogenesis. Nat Med (2000) 1.90
Chemistry of the hemostatic mechanism and its relationship to the action of heparin. Fed Proc (1977) 1.83
Correlation between structure and function of heparin. Proc Natl Acad Sci U S A (1979) 1.83
An antiproliferative heparan sulfate species produced by postconfluent smooth muscle cells. J Cell Biol (1985) 1.83
Molecular heterogeneity of inherited antithrombin III deficiency. N Engl J Med (1983) 1.75
Natural anticoagulant mechanisms. J Clin Invest (1984) 1.75
Vascular bed-specific expression of an endothelial cell gene is programmed by the tissue microenvironment. J Cell Biol (1997) 1.74
Anticoagulantly active heparin-like molecules from vascular tissue. Biochemistry (1984) 1.70
Conformational flexibility: a new concept for explaining binding and biological properties of iduronic acid-containing glycosaminoglycans. Trends Biochem Sci (1988) 1.66
Structure-function relationships of heparin species. Proc Natl Acad Sci U S A (1978) 1.65
Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun (1983) 1.62
Correlation of structure and adjuvant activity of N-acetyl muramyl-L-alanyl-D-isoglutamine (MDP), its derivatives and analogues. Anti-adjuvant and competition properties of stereoisomers. Biochem Biophys Res Commun (1976) 1.60
Expression of heparan sulfate D-glucosaminyl 3-O-sulfotransferase isoforms reveals novel substrate specificities. J Biol Chem (1999) 1.58
Spontaneous thrombosis in mice carrying the factor V Leiden mutation. Blood (2000) 1.58
Multiple isoforms of heparan sulfate D-glucosaminyl 3-O-sulfotransferase. Isolation, characterization, and expression of human cdnas and identification of distinct genomic loci. J Biol Chem (1999) 1.58
Absence of the blood-clotting regulator thrombomodulin causes embryonic lethality in mice before development of a functional cardiovascular system. Proc Natl Acad Sci U S A (1995) 1.58
Heparinlike molecules with anticoagulant activity are synthesized by cultured endothelial cells. Biochem Biophys Res Commun (1985) 1.56
Inhibition of activated factor XII by antithrombin-heparin cofactor. J Biol Chem (1976) 1.56
Treatment of coumarin-induced skin necrosis with a monoclonal antibody purified protein C concentrate. Arch Dermatol (1993) 1.55
Conformer populations of L-iduronic acid residues in glycosaminoglycan sequences. Carbohydr Res (1990) 1.53
Enzymatic modification of heparan sulfate on a biochip promotes its interaction with antithrombin III. Biochem Biophys Res Commun (2000) 1.51
Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest (1994) 1.50
Acceleration of thrombin-antithrombin complex formation in rat hindquarters via heparinlike molecules bound to the endothelium. J Clin Invest (1984) 1.48
Enhancement of certain biological activities of muramyl dipeptide derivatives after conjugation to a multi-poly(DL-alanine)--poly(L-lysine) carrier. Proc Natl Acad Sci U S A (1979) 1.48
Haemostatic changes that constitute the hypercoagulable state. Lancet (1991) 1.47
The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin. J Biol Chem (1980) 1.47
Isolation and characterization of heparin from human lung. J Clin Invest (1979) 1.46
Heparan sulfate D-glucosaminyl 3-O-sulfotransferase-3A sulfates N-unsubstituted glucosamine residues. J Biol Chem (1999) 1.45
Multiple functional domains of the heparin molecule. Proc Natl Acad Sci U S A (1981) 1.45
Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol (1988) 1.44
Purification and properties of human platelet heparitinase. J Biol Chem (1982) 1.42
Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest (1980) 1.42
Molecular cloning and expression of two distinct cDNA-encoding heparan sulfate proteoglycan core proteins from a rat endothelial cell line. J Biol Chem (1992) 1.41
Localization of anticoagulantly active heparan sulfate proteoglycans in vascular endothelium: antithrombin binding on cultured endothelial cells and perfused rat aorta. J Cell Biol (1990) 1.40
The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin III-binding sequence. Chemical and 13C nuclear-magnetic-resonance studies. Biochem J (1981) 1.39
Biologic actions of heparin. Semin Hematol (1977) 1.38
Contribution of zinc and other metals to the biological activity of the serum thymic factor. Proc Natl Acad Sci U S A (1982) 1.37
The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci U S A (1994) 1.36
The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood (1995) 1.35
Microvascular heparin-like species with anticoagulant activity. Am J Physiol (1983) 1.34
Mechanism of heparin activation of antithrombin. Role of individual residues of the pentasaccharide activating sequence in the recognition of native and activated states of antithrombin. J Biol Chem (1998) 1.34
Bone marrow graft in man after conditioning by antilymphocytic serum. Br Med J (1970) 1.32
Binding of lipoprotein lipase to endothelial cells in culture. J Biol Chem (1981) 1.31
The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation. Blood (1987) 1.31
Molecular cloning and expression of mouse and human cDNAs encoding heparan sulfate D-glucosaminyl 3-O-sulfotransferase. J Biol Chem (1997) 1.30
Improvement in mammography interpretation skills in a community radiology practice after dedicated teaching courses: 2-year medical audit of 38,633 cases. Radiology (1992) 1.30
Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells. J Cell Physiol (1984) 1.29
Structure of the rat platelet factor 4 gene: a marker for megakaryocyte differentiation. Mol Cell Biol (1987) 1.29
Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation (1994) 1.28
Transcriptional regulation of the rat platelet factor 4 gene: interaction between an enhancer/silencer domain and the GATA site. Mol Cell Biol (1991) 1.28
Systematically missing confounders in individual participant data meta-analysis of observational cohort studies. Stat Med (2009) 1.27
In vitro spleen cell responsiveness to various analogs of MDP (N-acetylmuramyl-L-alanyl-D-isoglutamine), a synthetic immunoadjuvant, in MDP high-responder mice. Cell Immunol (1978) 1.26
Enhancement of murine cardiac chronotropy by the molecular transfer of the human beta2 adrenergic receptor cDNA. J Clin Invest (1998) 1.25
Inhibition of human factor IXa by human antithrombin. J Biol Chem (1975) 1.25
Heparin with two binding sites for antithrombin or platelet factor 4. J Biol Chem (1982) 1.25
Apyrogenic, adjuvant-active N-acetylmuramyl-dipeptides. J Med Chem (1982) 1.25
Selective targeting of gene products with the megakaryocyte platelet factor 4 promoter. Proc Natl Acad Sci U S A (1991) 1.24
Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1 + 2 fragment and thrombin--antithrombin complex. Blood (1982) 1.24
Synthesis of N-acetyl-muramyl-L-alanyl-D-isoglutamine, an adjuvant of the immune response, and of some n-acetyl-muramyl-peptide analogs. Int J Pept Protein Res (1977) 1.23
6-O-sulfotransferase-1 represents a critical enzyme in the anticoagulant heparan sulfate biosynthetic pathway. J Biol Chem (2001) 1.23
Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. J Clin Invest (1981) 1.23
The effects of quality and timing of venepuncture on markers of blood coagulation in healthy middle-aged men. Thromb Haemost (1995) 1.23
Endothelial expression of thrombomodulin is reversibly regulated by fluid shear stress. Circ Res (1994) 1.22
Human von Willebrand factor gene sequences target expression to a subpopulation of endothelial cells in transgenic mice. Proc Natl Acad Sci U S A (1995) 1.20
Expression cloning of LDLB, a gene essential for normal Golgi function and assembly of the ldlCp complex. Proc Natl Acad Sci U S A (1999) 1.20
Isolation and characterization of heparan sulfate proteoglycans produced by cloned rat microvascular endothelial cells. J Biol Chem (1992) 1.20